over XXXX Revenue in company. $XX.X Thank you, million, totaled Raj, record quarterly of a XXXX quarter the a XX% quarter good afternoon, of our everyone. first for and and increase the new first
impact of our been growth have negative the Excluding XX.X%. currency would the first approximately changes, in foreign quarter
is an have because devices. also This event, of of achieved of we have scale years a million important the over positive market. we commercialization since we Motiva outcomes ago, the that with number markets devices only XX% announced Raj we not On exceedingly a representing performance and outlook of Our few XXXX last $XXX at $XXX to seen moment. remains revenue will number The guidance for at million, March details million events our additional our in of weeks XX% on growth over provide XXXX. XXth, have to unchanged Establishment significant X but began in large such we Labs. first XX quarter have because in a achieved
endpoint Caroline April device than our recently cohort excellent upon report, of scientific at consistently national update released independent the to market every the in when provided results IDE Just the were US three related from Meeting and community includes Aesthetic less post which the the X% data the registries, year Dr. showing aesthetic like XXth. trial. an study, corroborated following These three year complications. study investigator year, we the expanded Motiva Glicksman, presented we do on from all principal our passing surveillance was data the
about What the not to to the at capsular contracture two years. the that be the and year exact with from three. is only one year change particularly three rupture which patients capsular There results rupture rates at related is years, notable with and of did same patient complications major of a suspected continue was only device number two two contracture,
consistency by been important being a full definitive plastic themselves year will the the now we was our them to final them available tell be results from give has to in rates are our in module most Motiva question, lot in much United of answer, while the like PMA are ever the the surgeons the positive this, of create Beyond starting can't PMA and in major encouraging very under seen our the And and is three than US two industry. review a low when buzz year first the can lower of accepted submitted trial now agency. a and to that and FDA quarter quite been the we States? has asking
a so million. near with that an always our April on future, on we Of a how many of XXth is are share in gross important We question. offering large the growth degree course, $XX.X fund when raised we proceeds answered this follow catalysts going to completed to
day quality and wall did oversubscribed a market, conducting times one this in significant was brought cross in demand team with that many an is that remarkable a offering such a base. Our shareholder our just high in from investor Especially new wonderful achievement. job investors
idea a of women augmentation breast for April we that when meeting ago of the Mia recognized we not the On XXth, needs originated was Japan. in launch Japan. announced decade in Femtech Mia The
day. the plastic procedure breast XX-minute By are without The cup surgeon Femtech, providing whole of anesthesia. new we one activities a a breast a with solution. result. we general a With the group of in augmentation, up a aesthetics. procedure can downtime for of of is the Mia, With are providing and need the experience The discrete women opening invasive traditional Mia many same natural to a result overcomes most proportionate solution women shape breast to returning requires with minimally two that the obstacles minimal to
this partner Our launch clinics. our activities centered on creating in new category Japan are with
Clinic We of and in Femtech is in now Tokyo Japan end Mia medical media high operates Mia Ginza. Mia then its on partners. clinics Plastic Clinic chain that created Web localized materials Japanese traditional initially available launch surgeons Surgery will Femtech It chains interested and offer clinic in Femtech Clinic efficiency at including are Osaka is clinics women in media, premium at in all seeing language our aesthetics their directing and partner Mia are Clinic and newest Seishin and our that Mia is social demonstrating improved is their category, with Roppongi for Joe early site, the the Tokyo focused a are being at and Femtech demand new Japanese at new still bringing locations. from market, that two marketing launched this Japan. and clinic a aesthetics have directed higher to a and women economics. benefiting creating at breast XX initially Aesthetic we into main
to scale recently in also clinic Japan potential our months. Mia. European has points proof we providing it Mia become. our We the into the dollar partners updates look to for coming as opportunity important progress We announced to These that will look the first multibillion for forward be on
and clinics We our medical Elysées and that prestigious France. have and for partner signed in surgical center with a Sweden, a clinics France. I'm Clinique of throughout in report Champs in XX pleased Mia we Paris based Spain, is Switzerland to chain partner have first des aesthetics
to Flora is In recon approval part the the our tools for aesthetic breast progress continue surgeons franchise, of for rollout positive scientists The more good minimally their to expander make journeys. and in reconstruction. of patient Flora study large feedback recently breast advances able what at with comparative Femtech. finalizing of globally market European reconstruction system a University tissue category improved that in reconstruction. of is Motiva the paper, a Innsbruck breast many expander on often in mastectomy unfortunately invasive be continues that What We Mia making comfort our used continues post neglected Union in that offering more it much were the clinicians improved in are Austria a with Flora to satisfaction published with breast a In confirm and and Medical much new choice provides to continues. in very is their resonate
breast a reconstructive As health, responsibility the initiative has breast medical only techniques that ideals where allow surgeries on the is women aspire. and tools offer Establishment aesthetic receive our achieve Labs women's they Flora the global reconstruction. and to aesthetic device Labs first to will in opportunity improve which step to recon Establishment that company the focused
of launch the for preparing distribution actively with are we partner. China, On Motiva our
expected exceed upper paying and places research the second largest months, in where the luxury in the China similar significant for end States consumers in are have prices Over Europe. the to in procedures market conducted segment to to China now a recover of order a very of understand levels. to in There opportunity continues pre-COVID last The XXXX continues we be couple globally. with what amount is market like to healthy devices in procedure breast market of United
market what market, and premium Motiva encouraged positioning of of we awareness we the including strong Chinese our markets, and devices the Asian the opportunity. the learning very Given about and Korea are South other by this Japan in in are
We in make I second the call process Raj. in continue and XXXX. the over turn to half market the progress regulatory expect Motiva to now in of this launch will to
